East of England Health, Biotech & Nutrition R&D Companies Directory

Amgen is a global biotechnology leader focused on the discovery, development, and manufacture of innovative human therapeutics. The company leverages advanced biological research and genomic insights to address serious illnesses in areas such as oncology, cardiovascular disease, and inflammation. Their work integrates high-throughput screening and large-scale manufacturing to translate complex molecular biology into clinical solutions.

The National Institute of Agricultural Botany (NIAB) is a leading UK plant science research organisation that bridges the gap between fundamental research and practical agricultural application. They specialise in crop improvement, soil health, and pest management, frequently partnering with commercial growers and technology providers to validate and deploy sustainable farming innovations. Their work has evolved from traditional crop breeding into a highly interdisciplinary focus on precision agriculture, digital monitoring, and circular economy solutions for the UK horticultural sector.

Mologic is a diagnostics company specialising in point-of-care tests for infectious diseases, respiratory conditions, and animal health. They develop lateral flow assays, virus-like particle vaccines, and integrated digital diagnostic platforms, with a strong emphasis on affordable testing for global health and low-resource settings. Their work has evolved from stratified medicine projects for COPD and sepsis to large-scale global health initiatives in sub-Saharan Africa and, more recently, livestock diagnostics.

Arecor is a biotherapeutic formulation company specialising in developing stable formulations of therapeutic proteins, particularly for diabetes care. Their proprietary formulation technology enables improved stability and action profiles for insulin and glucagon, addressing unmet needs in glucose management. Their work has evolved from early proof-of-concept projects to clinical-stage products, including ultra-long acting, superfast acting, and ultra-rapid insulins, with a focus on enabling closed-loop artificial pancreas systems.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that has developed a proprietary platform technology based on bicyclic peptides, known as Bicycles. Their work focuses on creating a new class of therapeutics that combine the high affinity and specificity of antibodies with the small size and chemical versatility of small molecules. Across their grant history, they have evolved from feasibility studies in antibiotic discovery to applying their modular platform to address infectious diseases, including COVID-19 and multi-drug resistant bacterial infections.

Dogtooth Technologies is an agricultural robotics company that develops autonomous soft fruit harvesting systems, primarily for strawberries and raspberries. Their technology combines computer vision, machine learning, and robotic manipulation to address labour shortages and reduce food waste in horticulture. Over a decade of Innovate UK-funded R&D, they have evolved from proof-of-concept prototypes to commercial-scale robots deployed in UK and overseas farms.

Rothamsted Research is a world-leading agricultural science institute that focuses on developing sustainable solutions for crop production, soil health, and pest management. Their work bridges the gap between fundamental bioscience and practical on-farm application, frequently collaborating with commercial spin-outs and industry partners to translate research into field-ready technologies. Their portfolio has evolved from traditional plant pathology and entomology into advanced digital agriculture, biostimulants, and nature-based climate solutions.

Antikor Biopharma is a biopharmaceutical company pioneering the OptiLink platform for fragment-drug conjugates (FDCs), a novel class of targeted cancer therapeutics. Unlike traditional antibody-drug conjugates, their smaller format enables deeper tumour penetration, rapid clearance, and higher therapeutic index. Through a succession of Innovate UK grants, they have advanced a lead candidate (ANT-045) for gastric cancer to IND-enabling studies and expanded their pipeline to colorectal and ovarian cancers, demonstrating a consistent focus on difficult-to-treat solid tumours.

BiologIC Technologies develops 3D-printed biocomputer platforms for bioprocessing, integrating fluidics, electronics, optics, and pneumatics into programmable systems. Their technology targets synthetic biology applications including therapies, vaccines, diagnostics, and cultured meat, with a focus on enabling distributed, sustainable, and scalable biomanufacturing. The company's grant history shows progression from early feasibility studies on diagnostic hardware to advanced platforms for RNA and cell/gene therapy manufacturing, with an increasing emphasis on sustainability and commercialisation.

The John Innes Centre is a world-leading independent research institute specialising in plant science, genetics, and microbiology. Their work focuses on enhancing crop resilience, improving nutritional quality, and developing sustainable agricultural practices through advanced genomic and biotechnological research. Over their grant history, they have evolved from fundamental plant research into a key partner for commercialising precision breeding and soil health technologies within the UK agri-tech sector.

SugaROx develops biostimulant formulations based on a novel active ingredient inspired by trehalose-6-phosphate (T6P), a natural sugar that regulates carbon use and allocation in plants. Founded in 2021 as a spin-out from Oxford University and Rothamsted Research, the company aims to improve crop productivity, resilience, and sustainability. Its grant history shows progression from feasibility studies to large-scale field trials and product commercialisation targeting wheat, tomato, and global commodity crops.

Sentinel Oncology is a biopharmaceutical company developing small molecule therapies for central nervous system disorders and cancers. Their pipeline includes treatments for Fragile X Syndrome (SOL101), Alzheimer's disease, and glioblastoma (SOL288), targeting underlying disease mechanisms rather than symptoms. The company has progressed from preclinical proof-of-concept to early-stage clinical development, funded entirely through Innovate UK grants as lead partner.

FOLIUM Science uses CRISPR gene editing technology (branded as Guided Biotics) to develop targeted bacterial control solutions for agriculture and food production, replacing antibiotics and reducing environmental emissions. Their work has evolved from feasibility studies on biofilm disruption to commercial products for Campylobacter and ammonia reduction in poultry, demonstrating a clear trajectory from fundamental research to commercialisation. The company collaborates extensively with academic institutions and research organisations.

Lightpoint Medical develops novel intra-operative cancer detection probes based on beta particle detection, allowing surgeons to locate cancerous tissue in real-time during laparoscopic and robotic surgery. The company has progressed from concept to clinical evaluation, focusing on prostate, head and neck, and colorectal cancers, with products including EnLight and LightPath Imaging System.

TidalSense (formerly Cambridge Respiratory Innovations Ltd) develops a low-cost personal respiratory monitor called N-Tidal that uses an advanced LED-based CO2 sensor to analyse tidal breathing waveforms. The company focuses on enabling early detection and monitoring of respiratory conditions such as COPD and asthma, aiming to predict exacerbations and improve disease management. Since 2016, they have progressed from feasibility studies through clinical validation to developing connected remote monitoring systems.

Tusk Therapeutics is a UK biotechnology company focused on developing novel immune-modulating antibodies for cancer therapy. Their lead preclinical candidate, TSK011010, is a fully human anti-CD38 antibody designed to harness the immune system against cancer. The company's only Innovate UK grant was withdrawn in 2017/18, halting late-stage development.

Entomics Biosystems is a UK biotechnology company that uses insect bioconversion to transform organic waste into sustainable animal feed, biofertiliser, and potentially food products. They develop modular insect production systems and post-processing technologies, initially focusing on waste management and then scaling to aquaculture and poultry feed applications. Their research has evolved from a waste management concept to building a regulatory network to expand insect bioconversion in the UK.

Alchemab Therapeutics is a biotechnology company focused on identifying and developing protective 'self'-antibodies derived from resilient individuals to treat neurodegenerative conditions. By analysing B cells from patients who resist disease despite genetic predisposition, the company seeks to translate natural resilience into therapeutic interventions. Their work has evolved from initial molecular target identification in Huntington's disease to advanced pre-clinical development and manufacturability assessment.

Maxion Therapeutics is a UK biotechnology company developing a novel therapeutic platform called KnotBodies, which fuses ion channel-modulating mini-proteins (knottins) from venoms with antibodies to target ion channel-driven diseases. Their technology aims to address chronic pain, autoimmune disorders, and heart disease by combining the specificity of antibodies with the ion channel modulation of knottins. The company has progressed from initial platform validation to late-stage preclinical development of Kv1.3 blockers for autoimmune diseases.

Plasticell is a small biotechnology company specialising in combinatorial cell culture and stem cell technologies. They develop protocols and manufacturing processes for generating blood cells and immune cells from pluripotent stem cells, aiming to create off-the-shelf cell therapies for blood disorders and cancer. Their work has evolved from generating red blood cells for transfusion to advanced gene therapy manufacturing and iPSC-derived CAR-NK immunotherapies.